NGM Bio
Medical AI · Drug Discovery
$142Mlatest round · Venture round · Jul 2024 · 2 yr ago
1backers · Foresite Capital
500+team · employees, estimated range
2024founded
Overview
Ngmbio develops life-changing medicines rooted in powerful biology, including NGM120 for hyperemesis gravidarum and cancer cachexia.
Funding and backers
Total raised
$142M
1 round on record
Latest round
$142M
Venture round · Jul 2024 · 2 yr ago
Team
501-1000
employees, estimated range
Backers
1
Foresite Capital
The money's age
Long since its last round
28 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 4, 2025
New executive NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer · The Manila Times
Jul 5, 2024
Raised a round Venture round $142M · SEC Form D
2024
Founded
Jun 30, 2022
New executive NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer · Nasdaq
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2024 | $142M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | NGM Bio Holdings, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kara CalhounExecutive OfficerSEC Form D
Hsiao LieuExecutive OfficerSEC Form D
David WoodhouseExecutive Officer, DirectorSEC Form D
Daniel KaplanExecutive OfficerSEC Form D
Valerie PierceExecutive OfficerSEC Form D
Jean-Frederic ViretExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Drug discovery at the resolution of biology. Using the power of the transcriptome to discover revolutionary medicines.
Zymedi leverages ARS biology to discover novel therapeutics and first-in-class drugs for patients.
Revilico is digitizing pharmaceutical R&D, empowering every chemist and biologist with unified virtual simulations, AI models, and closed…
Kriya is building durable medicines designed to replace chronic re-treatment with a single administration—therapeutic medicines that can…
Abbott develops life-changing medical devices for cardiovascular conditions.
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
Financials
Total raised
$142M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $142M | Details |
People
Kara Calhoun
Executive Officer
Hsiao Lieu
Executive Officer
David Woodhouse
Executive Officer, Director
Daniel Kaplan
Executive Officer
Valerie Pierce
Executive Officer
Jean-Frederic Viret
Executive Officer
Diana Bockus
Executive Officer, Director
Roger Perlmutter
Director
William Rieflin
Director
Shelly Guyer
Director
David Goeddel
Director
Peter Svennilson
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Foresite CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
media531546,531547
Read more
Report
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
media496481,496482
Read more
Report
NGM Bio Announces Closing of Tender Offer - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
Read more
Report
Report
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
--NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Siobhan Nolan Mangini, who has served as the company' s Chief Financial Officer since July 2020, h
Read more
Report
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
--The four-part series titled the
Read more
Report
NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
--NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NGM621, a monoclonal a
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
South San Francisco
United States
HQ
500-1000 est. staff
611 Gateway Blvd., Suite 540, South San Francisco, CA 94080